IBD Occurrence in Patients Treated with Psoriasis Drug

September 7, 2017

Despite growing worry that drugs used to treat plaque psoriasis may also cause inflammatory bowel disease (IBD) in patients, a recent study in the American Journal of Dermatology found that new cases of IBS occurred in less than 1% of patients exposed to Taltz (ixekizumab; Eli Lilly), according to a Pharmacy Times report.

“Inflammatory bowel disease occurs more frequently in patients with psoriasis,” researchers wrote in the study (doi: 10.1016/j.jaad.2016.10.027). “The 2 diseases have significant genetic overlap, but the pathogenesis underlying their co-occurrence is unknown.”

To gauge the incidence of Crohn’s disease and ulcerative colitis in people taking the psoriasis drug ixekizumab, researchers analyzed adverse events for 4209 patients (6480 patient-exposure years) from 7 complete and ongoing trials.

Just 29 patients reported suspected Crohn’s disease (12) or ulcerative colitis (17), researchers reported. Of those cases, 19 were adjudicated as probable or definite cases.

Meanwhile, among 16 patients who had a history of IBD, 12 reported no treatment-emergent IBD, the analysis showed.

“The rates of new IBD cases were uncommon,” Pharmacy Times reported (August 30, 2017). “Furthermore, flares of preexisting disease were also found to be a rare occurrence.”

Jolynn Tumolo